Marc Nasoff, Ph.D.

Chief Scientific Officer, Biologics

Marc Nasoff brings over 35 years of industry experience to COI Pharmaceuticals and currently serves as the company’s chief scientific officer.

Most recently, he served as the director of biologics at GNF, a subsidiary of Novartis Pharma, where he worked closely with Novartis Biologics on the development of human therapeutic antibodies. Before moving to San Diego to become research director for Pharmacia, Dr. Nasoff worked at Genetics Institute in Boston.

Dr. Nasoff received his Ph.D. in microbial genetics from the University of Maryland. This was followed by postdoctoral training in organic synthesis at the University of Colorado. Dr. Nasoff has authored more than 50 patents and 30 publications.


in the news

  • Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

    read more
  • COI Can: World Cancer Day

    read more
  • What does COI look for in an investment opportunity?

    read more